How to Verify a GLP-1 Pharmacy: Compounded vs. Brand Safety, Legal Status, and FDA Rules

Why Pharmacy Verification Matters Before You Fill a GLP-1 Prescription

Getting the right pharmacy is not a formality. The FDA has issued multiple warning letters and seized products from vendors selling semaglutide and tirzepatide acetate salt forms, which are not the same active moiety as the FDA-approved free-base peptides in Wegovy and Zepbound [1]. A patient filling a prescription at an unverified source may receive a product with incorrect concentration, undisclosed excipients, or no sterility assurance at all.

The clinical stakes are real. In STEP-1 (N=1,961), subcutaneous semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [2]. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks versus 2.4% with placebo (P<0.001) [3]. Those outcomes were generated with pharmaceutical-grade, stability-tested product. A counterfeit or improperly compounded version carries no equivalent data and introduces unknown risk.

Three credentials confirm a legitimate pharmacy. First, an active state pharmacy license verifiable through your state board of pharmacy website. Second, National Association of Boards of Pharmacy (NABP) accreditation, displayed as a .pharmacy domain or a NABP Verified seal. Third, for compounders specifically, either 503A licensure (state-regulated, patient-specific) or 503B FDA registration, verifiable at the FDA's registered outsourcing facilities list [4].

Understanding the FDA Shortage List and Why It Governed Compounding Access

The FDA Drug Shortages database is the single regulatory switch that determined whether 503B outsourcing facilities could legally produce copies of brand GLP-1 drugs [5]. When a drug is on the shortage list, Section 503B of the Federal Food, Drug, and Cosmetic Act permits FDA-registered outsourcing facilities to compound copies of that drug even without individual patient prescriptions, provided they meet Current Good Manufacturing Practice (CGMP) standards.

Both major GLP-1 drugs spent years on that list. Tirzepatide shortages were resolved in October 2024 [5]. Semaglutide shortages were resolved in February 2025 [5]. Once a shortage resolves, the 503B mass-compounding exemption disappears. Pharmacies that continued producing bulk compounded semaglutide after February 2025 were operating outside the legal framework. The FDA's guidance published in March 2025 gave 503B facilities a 60-day wind-down period for semaglutide and a 90-day period for tirzepatide [4].

503A pharmacies, regulated primarily by state boards rather than the FDA, retain the ability to compound patient-specific formulations when a licensed prescriber determines a commercial product does not meet a specific patient's clinical need. That pathway remains open as of mid-2025, but it requires an individualized prescriber assessment and a patient-specific prescription. No telehealth platform can legally route patients to a 503A compounder using a standing protocol that treats all patients identically.

503A vs. 503B: What the Difference Means for Your Safety

The distinction between 503A and 503B shapes nearly every quality metric you should care about as a patient. 503B outsourcing facilities must comply with FDA CGMP, undergo biennial FDA inspections, and test finished products for potency, sterility, and endotoxins before release [4]. 503A pharmacies follow US Pharmacopeia (USP) Chapter 797 sterile compounding standards enforced by state boards, which vary in inspection frequency and rigor.

Neither standard equals the full New Drug Application (NDA) process that produced Wegovy [6] and Zepbound [7]. Brand-name drugs undergo phase III randomized controlled trials, multi-lot stability studies, and post-market pharmacovigilance. Compounded products do not.

From a practical standpoint, a patient receiving compounded semaglutide from a properly licensed 503A pharmacy faces a different risk profile than one ordering from a website with no verifiable US license. The former involves a state-licensed pharmacist, a valid prescription, and USP 797 sterility compliance. The latter may involve a research chemical vendor relabeling lyophilized powder. The FDA's MedWatch database recorded adverse events linked to compounded semaglutide products including hypoglycemia, nausea requiring hospitalization, and dosing errors attributed to variable concentration vials [8].

The HealthRX Pharmacy Verification Framework uses four checkpoints before any GLP-1 prescription is routed:

1. License check. Confirm active status on the state board website of the pharmacy's physical location.
2. NABP credential. Verify a .pharmacy domain or a current NABP accreditation certificate with a non-expired date.
3. FDA registration. For any compounder, search the FDA's 503B outsourcing facility registry at fda.gov. A 503A pharmacy will not appear there; confirm its state license explicitly.
4. Prescription requirement. Any source dispensing GLP-1 medications without a valid US prescriber relationship is operating illegally under 21 U.S.C. 353(b).

How to Check Whether a GLP-1 Pharmacy Is Legitimate

Start with the NABP's pharmacy verification portal at nabp.pharmacy. The NABP's .pharmacy accreditation program requires pharmacies to pass a screening that checks US licensure, prescriber-patient relationship policies, and compliance with state and federal law [9]. The NABP also maintains a "Not Recommended" list of online pharmacies that fail those standards. Checking both the accredited list and the not-recommended list takes under two minutes.

The FDA's database of registered 503B outsourcing facilities is updated monthly and is searchable by facility name, city, and state [4]. If a pharmacy claims 503B status but does not appear in that database, the claim is false.

State board of pharmacy license lookup tools are available for all 50 states through the NABP's CPE Monitor or directly through individual board websites. Enter the pharmacy's name and zip code. A valid license will show current status, license number, and expiration date. A suspended or expired license is an absolute disqualifier.

Price is a secondary signal but a useful one. The wholesale acquisition cost for Wegovy (semaglutide 2.4 mg, 4-week supply) was approximately $1,349 as of early 2025. Compounded semaglutide from a properly licensed 503A pharmacy typically ran $200 to $400 per month during the shortage period. Offers below $100 per month for injectable GLP-1 drugs almost certainly reflect unlicensed international sourcing or research-grade chemicals not intended for human use.

Compounded vs. Brand GLP-1 Safety: What the Clinical Evidence Shows

Brand-name semaglutide and tirzepatide carry the largest clinical trial safety datasets of any obesity pharmacotherapy to date. The SELECT trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo over a mean follow-up of 34.2 months in adults with established cardiovascular disease and overweight or obesity (hazard ratio 0.80 to 95% CI 0.72 to 0.90, P<0.001) [10]. That cardiovascular benefit is inseparable from the manufacturing and formulation standards of the approved drug.

SURMOUNT-4 (N=670) demonstrated that patients who discontinued tirzepatide after 36 weeks of treatment regained approximately 14% of body weight over the subsequent 52 weeks, versus continued loss in those who maintained therapy [11]. That trajectory underscores that patients are making long-term treatment decisions, not one-time purchases, making pharmacy reliability a clinical issue rather than merely a logistical one.

The AACE/ACE Obesity Clinical Practice Guidelines note that anti-obesity medications should be prescribed "as part of a comprehensive program including diet, physical activity, and behavioral counseling" [12]. That standard requires a sustained prescriber-pharmacy relationship, not a one-time online transaction.

Direct comparative safety data between brand and compounded GLP-1 products does not exist in the peer-reviewed literature as of mid-2025, because compounded products are not studied in registered trials. What does exist is pharmacokinetic equivalence logic: semaglutide in Wegovy is the free-base form, whereas some compounders used semaglutide sodium or semaglutide acetate. The FDA explicitly stated these salt forms "are not the same drug product" as Ozempic or Wegovy and cannot be assumed to have equivalent bioavailability or safety [8].

STEP-5 (N=304 to 104 weeks) showed that semaglutide 2.4 mg maintained a 15.2% mean weight loss with a well-characterized adverse event profile dominated by transient gastrointestinal effects [13]. Patients and clinicians relying on that tolerability data are implicitly assuming a consistent formulation.

What Telehealth GLP-1 Platforms Are Required to Do

Any telehealth company prescribing GLP-1 medications must maintain a valid prescriber-patient relationship under the Ryan Haight Online Pharmacy Consumer Protection Act and applicable state telehealth laws. That relationship requires at minimum a synchronous or documented asynchronous clinical evaluation, a reviewed medical history, and documentation of a legitimate clinical indication.

The FDA's prescribing information for Wegovy specifies an initial BMI indication of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia [6]. Platforms that approve prescriptions without collecting BMI, comorbidity history, or contraindication screening are violating the terms of the approved labeling.

STEP-3 (N=611) combined semaglutide 2.4 mg with intensive behavioral therapy and produced 16.0% mean weight loss at 68 weeks versus 5.7% with placebo plus intensive behavioral therapy (P<0.001) [14]. That data was generated in a structured clinical program. Telehealth platforms replicating that structure, with licensed prescribers, registered pharmacies, and follow-up protocols, are the legitimate model.

Red flags specific to telehealth GLP-1 prescribing include: approval in under five minutes without a clinical questionnaire, no state-licensed physician or NP name on the prescription, shipping from addresses outside the continental United States, and vials labeled "research use only" or "not for human use."

Semaglutide and Tirzepatide Shortage Status in 2025

The FDA resolved the tirzepatide shortage in October 2024 and the semaglutide shortage in February 2025 [5]. Both drugs are listed as commercially available in sufficient supply through the FDA Drug Shortages database. The resolution of these shortages ended the 503B mass-compounding exemption for both drugs under FD&C Act Section 506E.

The FDA issued guidance in March 2025 specifying that 503B facilities had 60 days from the semaglutide shortage resolution to stop producing and distributing copies of Ozempic or Wegovy, and 90 days for tirzepatide copies [4]. Facilities continuing after those deadlines are subject to Warning Letters, injunctions, and product seizures.

503A pharmacies retain more flexibility. A licensed 503A pharmacy may compound semaglutide or tirzepatide if the prescriber documents a clinical necessity that the brand product cannot fulfill, such as an allergy to an excipient in the commercial product or a documented need for a dose not available in the commercial titration schedule. Generic documentation stating "patient preference" or "cost" does not satisfy the clinical necessity requirement under current FDA policy.

STEP-2 (N=1,210, Lancet 2021) studied semaglutide 2.4 mg in adults with type 2 diabetes and found 9.6% mean weight loss at 68 weeks versus 3.4% with placebo [15]. In that diabetic population, the active comparator semaglutide 1.0 mg (Ozempic dose) produced 7.0% weight loss. Both are brand formulations with stable, validated manufacturing.

How to Report a Suspected Illegal GLP-1 Vendor

The FDA MedWatch program accepts reports of adverse events from compounded or counterfeit drug products at fda.gov/safety/medwatch [8]. The FDA's Office of Criminal Investigations (OCI) accepts tips about unlicensed pharmacy operations. NABP accepts consumer complaints about pharmacies through nabp.pharmacy.

Reports should include the pharmacy name, website URL, order confirmation if available, product photos, lot number, and any adverse effects experienced. The FDA has used MedWatch data to support Warning Letters and consent decrees against compounding pharmacies operating outside 503A or 503B standards.

SURMOUNT-2 (N=938, Lancet 2023) showed tirzepatide 15 mg produced 15.7% mean weight loss in adults with type 2 diabetes at 72 weeks versus 3.3% with placebo [16]. That trial enrolled patients at academic medical centers using pharmaceutical-grade tirzepatide. Patients who received subpotent compounded product would not have reached those endpoints.

SURMOUNT-3 (N=579, Nature Medicine 2023) found that patients who completed a 12-week lifestyle intervention before starting tirzepatide lost a total of 26.6% of body weight through 72 weeks [17]. Both the lifestyle phase and the drug phase depend on a functional clinical infrastructure.

The FDA's Zepbound prescribing information specifies contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and prior serious hypersensitivity to tirzepatide [7]. No unlicensed vendor can reliably screen for those contraindications.

STEP-8 (N=338, JAMA 2022) compared semaglutide 2.4 mg to liraglutide 3.0 mg and found 15.8% mean weight loss with semaglutide versus 6.4% with liraglutide at 68 weeks (P<0.001) [18]. The magnitude of that difference reinforces why patients choose GLP-1 therapy, and why receiving substandard product represents a clinically meaningful harm.